(Q46952217)

26 December 2017

title

High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma (English)

1 reference

26 December 2017

main subject

torin 2

1 reference

ChEBI release 2020-05-28

7

1 reference

26 December 2017

author name string

Maqbool Ahmed

1

1 reference

26 December 2017

Azhar R Hussain

2

1 reference

26 December 2017

Prashant Bavi

3

1 reference

26 December 2017

Saeeda O Ahmed

4

1 reference

26 December 2017

Saif S Al Sobhi

5

1 reference

26 December 2017

Fouad Al-Dayel

6

1 reference

26 December 2017

Khawla S Al-Kuraya

8

1 reference

26 December 2017

language of work or name

English

0 references

publication date

28 February 2014

1 reference

26 December 2017

published in

Carcinogenesis

1 reference

26 December 2017

volume

35

1 reference

26 December 2017

page(s)

1564-1572

1 reference

26 December 2017

issue

7

1 reference

26 December 2017

Increasing incidence of thyroid cancer: controversies explored

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

New targeted therapies for thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Approach to the patient with advanced differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Thyroid cancer: molecular aspects and new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

The evolution of the TOR pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Role of mTOR signaling in tumor cell motility, invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

The complexes of mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Targeting mTOR for the treatment of AML. New agents and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

mTOR kinase inhibitors as potential cancer therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Targeted-therapy in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Phosphorylated 4E-BP1 is associated with poor survival in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

Generation and characterization of antibodies specific for caspase-cleaved neo-epitopes: a novel approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU051

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGU051

1 reference

26 December 2017

PubMed ID

24583924

1 reference

26 December 2017